GLP-1s were associated with lower risk of complications for those already having a substance use disorder Among people who already had a substance use disorder, starting a GLP-1 medication was associated with fewer substance-related emergency department visits, hospital admissions, overdose events, episodes of suicidal ideation or attempts, and lower mortality (see graph below)
Tirzepatides Phase 3 programme is four years deeper, its three FDA approvals span type 2 diabetes, chronic weight management and obstructive sleep apnoea, and its published cardiovascular outcomes trial in more than thirteen thousand patients is a fact we do not dispute 12 28
Designed to target loose, crepey skin often seen after weight loss, this powerful formula lifts, tightens, and smooths for a refreshed and revitalized look
clinical presentation Onset is gradual and subacute, over several days
While these drugs hold incredible promise, off-label use is a gray areaand one that comes with both potential benefits and risks
